[LncRNA PVT1 Regulates the MiR-20a-5p/HMGA2 Signaling Axis to Affect Proliferation and Apoptosis of Diffuse Large B-Cell Lymphoma Cells] [0.03%]
长链非编码RNA PVT1通过调节MiR-20a-5p/HMGA2信号轴影响弥漫大B细胞淋巴瘤增殖及凋亡的功能研究
Xiao-Wei Xu,Wutikuer Adina,Hong-Li Zhang et al.
Xiao-Wei Xu et al.
Objective: To investigate the effect of long non-coding RNA (lncRNA) PVT1 on proliferation and apoptosis of diffuse large B-cell lymphoma (DLBCL) cells and the underlying mechanisms. ...
[EBNA1 Knockdown Modulates Proliferation, Apoptosis, and Metabolism in Burkitt's Lymphoma Cells by Downregulating miR-127-5p] [0.03%]
EBNA1低表达通过下调miR-127-5p调控伯基特淋巴瘤细胞增殖、凋亡及代谢
Shun-Yong Wang,Yan Wang,Han-Jing Li et al.
Shun-Yong Wang et al.
Objective: To preliminarily elucidates the role of EBNA1 in epigenetically regulating miR-127-5p and influencing the proliferation, apoptosis, and metabolism of Burkitt's lymphoma (BL) cells. ...
[The Relationship between OPN, NLR and Chemotherapy Efficacy in Patients with Acute Myeloid Leukemia] [0.03%]
血浆骨桥蛋白及中性粒细胞淋巴细胞比值与急性髓系白血病化疗疗效的关系
Jing-Jing Yu,Kai DU,Xiao-Dong Zhang
Jing-Jing Yu
Objective: To analyze the relationship between osteopontin (OPN), neutrophil/lymphocyte ratio (NLR) and chemotherapy efficacy in patients with acute myeloid leukemia (AML). ...
[Clinical Characteristics and Prognosis of Children with Relapsed Acute Lymphoblastic Leukemia] [0.03%]
儿童复发急性淋巴细胞白血病的临床特征及预后分析
Zhen-Song Zhao,Li-Lian Yang,Li-Zhi Wen et al.
Zhen-Song Zhao et al.
Objective: To investigate the clinical characteristics and prognosis of children with relapsed acute lymphoblastic leukemia (ALL). Methods: ...
[Analysis of Clinical Characteristics and Prognosis in Patients with NCAM1-Positive Acute Myeloid Leukemia] [0.03%]
NCAM1阳性急性髓系白血病患者的临床特征和预后分析
Zhong-Li Hu,Meng-Qing Hua,Jia-Jia Li et al.
Zhong-Li Hu et al.
Objective: To analyze the expression of NCAM1 in the bone marrow of patients with acute myeloid leukemia (AML), explore the clinical characteristics of NCAM1+AML patients, and investigate the impact of NCAM1 on the progno...
[Clinical Analysis of Blinatumomab in the Treatment of 21 Children with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia] [0.03%]
布利珠单抗治疗复发/难治性B细胞急性淋巴细胞白血病21例临床分析
Yu-Juan Xue,Yu Wang,Ai-Dong Lu et al.
Yu-Juan Xue et al.
Objective: To evaluate the efficacy and safety of blinatumomab in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), and to explore the factors affecting the efficacy of bl...
[Observation of the Therapeutic Effect of Venetoclax Combined with HEA Regimen on Acute Myeloid Leukemia Patients with KMT2A Gene Rearrangement] [0.03%]
伏立诺他联合HEA方案治疗KMT2A基因重排急性髓系白血病患者的疗效观察
Shan-Dong Tao,Rong Wen,Jia-Xin Li et al.
Shan-Dong Tao et al.
Objective: To observe the treatment response rate and safety of the combination of venetoclax and HEA (VHEA) regimen in the induction therapy of acute myeloid leukemia (AML) patients with KMT2A gene rearrangement. ...
[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review] [0.03%]
[无BCR-ABL的三阴性骨髓增生性肿瘤--综述]
Xiao-Yan Xu,Jie Yang,Yong-Bin Yang et al.
Xiao-Yan Xu et al.
Triple-negative myeloproliferative neoplasms (TN-MPN) are diseases characterized by absence of the three driver mutations in JAK2, CALR, or MPL, but still exhibit histological and phenotypic features sufficient to diagnose myeloproliferativ...
[The Research Progress of PI3K Inhibitors in the Treatment of Lymphoma --Review] [0.03%]
PI3K抑制剂治疗淋巴瘤的研究进展——文献复习
Wen-Jin Qiang,De-Li Kong,Xing-Bin Dai
Wen-Jin Qiang
There is a complex biological mechanism in the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt)/mammalian target of rapamycin (mTOR) signaling pathway, which plays a key role in the development and development of lymphoma. In...
[Recent Research Advances in Classification and Treatment of Primary Cutaneous Lymphoma--Review] [0.03%]
[原发性皮肤淋巴瘤分类和治疗的新进展-综述]
Jian Yang,Hong Zheng,Ahongjiang Yiliya et al.
Jian Yang et al.
Primary cutaneous lymphoma (PCL) is a group of heterogeneous diseases. Traditional chemotherapy methods often result in substantial toxic side effects due to their low tumor selectivity. Currently, individualized therapy based on the geneti...